 CytoDyn Inc has told investors that data from its trial treating non-alcoholic steatohepatitis NASH with its flagship drug leronlimab are encouraging and an exciting step forward in demonstrating the potential of the drug for inhibiting the liver fibrosis associated with NASH. The late-stage biotechnology company said the open-label NASH results continue to show reductions in fat and fibrosis suggestive of a potential therapy not only for non-alcoholic fatty liver deposit but also in NASH. 